Study S002605

The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT07021443
Acronym: GLP1_NAFLD
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 50
Start: 2023-10-09
Primary completion: 2023-10-26
Lead sponsor: Universitair Ziekenhuis Brussel
Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: OTHER:non-interventional
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Serum Markers (sfG) to Follow the Evolution of Liver Damage [From time of infomed consent till 1 year after signing informed consent.]
Fatty Liver Index (FLI) [From time of signing the ICF till 1 year after given informed consent]
FIB-4 Index [From time of signing the ICF till 1 year after given informed consent]
Serum Markers (HbA1c) to Follow the Evolution of Liver Damage [From time of infomed consent till 1 year after signing informed consent.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.